*** Welcome to piglix ***

Telmisartan

Telmisartan
Telmisartan.svg
Clinical data
Trade names Micardis
AHFS/Drugs.com Monograph
MedlinePlus a601249
Pregnancy
category
  • AU: D
  • US: D (Evidence of risk)
Routes of
administration
Oral
ATC code C09CA07 (WHO)
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability 42–100%
Protein binding >99.5%
Metabolism Minimal hepatic (glucuronidation)
Biological half-life 24 hours
Excretion Faecal 97%
Identifiers
CAS Number 144701-48-4 YesY
PubChem (CID) 65999
IUPHAR/BPS 592
DrugBank DB00966 YesY
ChemSpider 59391 YesY
UNII U5SYW473RQ YesY
KEGG D00627 YesY
ChEBI CHEBI:9434 YesY
ChEMBL CHEMBL1017 YesY
ECHA InfoCard 100.149.347
Chemical and physical data
Formula C33H30N4O2
Molar mass 514.617 g/mol
3D model (Jmol) Interactive image
  

Telmisartan (INN) /tɛlmɪˈsɑːrtən/ is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the management of hypertension. It was discovered by Boehringer Ingelheim and launched in 1999 as Micardis.

In January 2014, Actavis as generic version of Micardis got appoval from FDA.

Telmisartan is indicated in the treatment of essential hypertension.

Telmisartan is contraindicated during pregnancy. Like other drugs affecting the renin-angiotensin system (RAS), telmisartan can cause birth defects, stillbirths, and neonatal deaths. It is not known whether the drug passes into the breast milk. Also it is contraindicated in bilateral renal artery stenosis in which it can cause renal failure.

Side effects are similar to other angiotensin II receptor antagonists and include tachycardia and bradycardia (fast or slow heartbeat), hypotension (low blood pressure), edema (swelling of arms, legs, lips, tongue, or throat, the latter leading to breathing problems), and allergic reactions.


...
Wikipedia

...